Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
171.37
354.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc
Cash from Financing Activities
Madrigal Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
Cash from Financing Activities
$1.2B
|
CAGR 3-Years
97%
|
CAGR 5-Years
326%
|
CAGR 10-Years
24%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$2.8B
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$6.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$5.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$1.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Madrigal Pharmaceuticals Inc
Glance View
In the competitive and complex landscape of pharmaceuticals, Madrigal Pharmaceuticals Inc. has carved a niche for itself by focusing on the development of innovative therapies for metabolic and liver diseases. Founded with the visionary zeal to address unmet medical needs, Madrigal's journey is grounded in its dedication to advancing science and transforming patient care. The company's primary research and development efforts center around addressing non-alcoholic steatohepatitis (NASH), a significant liver condition that lacks approved treatments. With a keen eye on scientific innovation, Madrigal invests heavily in creating solutions for conditions that are not only challenging but also growing in prevalence, thus embodying the dual mission of driving better health outcomes and capturing market opportunities. Madrigal's business model is largely reliant on the successful progression of its lead candidate, resmetirom, through clinical trials and regulatory approval processes. This strategy, typical in the pharmaceutical arena, involves rigorous stages of testing to ensure efficacy and safety, aiming to bring the drug to market where it can address the substantial need. Revenue generation for Madrigal is intrinsically linked to licensing agreements, strategic partnerships, and eventual drug sales post-approval. This approach necessitates significant initial investment and patience, with the expectation of substantial returns contingent upon successful product commercialization. Through this focus, Madrigal advances towards not only improving the therapeutic landscape for liver diseases but also carving out a significant presence in the biotech market.
See Also
What is Madrigal Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
1.2B
USD
Based on the financial report for Sep 30, 2024, Madrigal Pharmaceuticals Inc's Cash from Financing Activities amounts to 1.2B USD.
What is Madrigal Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
24%
Over the last year, the Cash from Financing Activities growth was 215%. The average annual Cash from Financing Activities growth rates for Madrigal Pharmaceuticals Inc have been 97% over the past three years , 326% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
